Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-lindau disease: Targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 2, 2009, Pages 386-391

  Jimenez, Camilo ^a   Cabanillas, Maria E ^a   Santarpia, Libero ^a   Jonasch, Eric ^a   Kyle, Karen L ^a   Lano, Elizabeth A ^a   Matin, Surena F ^a   Nunez, Rodolfo F ^a   Perrier, Nancy D ^a   Phan, Alexandria ^a   Rich, Thereasa A ^a   Shah, Beejal ^a   Williams, Michelle D ^a   Waguespack, Steven G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ATENOLOL; CATECHOLAMINE; CHROMOGRANIN A; FLT3 LIGAND; NORMETADRENALIN; PHENOXYBENZAMINE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PRAZOSIN; PROTEIN RET; STEM CELL FACTOR; SUNITINIB; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; BLOOD PRESSURE; CASE REPORT; CATECHOLAMINE BLOOD LEVEL; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG TARGETING; FATIGUE; FEMALE; HEALTH STATUS; HUMAN; HUMAN TISSUE; KIDNEY TUMOR; LYMPH NODE METASTASIS; MOUTH PAIN; MULTIPLE CYCLE TREATMENT; NAUSEA; PANCREAS ISLET CELL TUMOR; PANCREAS TUMOR; PELVIS PAIN SYNDROME; PELVIS TUMOR; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SACRUM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR BIOPSY; VON HIPPEL LINDAU DISEASE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 59749100013     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1972     Document Type: Article

References (25)

1. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E 1998 Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394:485-490
2. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ 1999 The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275
3. Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER 2001 Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 10:1029-1038
4. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH 2003 von Hippel-Lindau disease. Lancet 361:2059-2067
5. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB 2007 The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 14:569-585
6. Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H 2007 Clinical review: Current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 92:1217-1225
7. 131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl Med Commun 26:969-976
8. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS 2006 Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401-406
9. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP 1982 Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655
10. Rathmell WK, Hickey MM, Bezman NA, Chmielecki CA, Carraway NC, Simon MC 2004 In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Cancer Res 64:8595-8603
11. Pollard PJ, El-Bahrawy M, Poulsom R, Elia G, Killick P, Kelly G, Hunt T, Jeffery R, Seedhar P, Barwell J, Latif F, Gleeson MJ, Hodgson SV, Stamp GW, Tomlinson IP, Maher ER 2006 Expression of HIF-1α, HIF-2α (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J Clin Endocrinol Metab 91:4593-4598
12. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP 1997 The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 17:5629-5639
13. Chow LQ, Eckhardt SG 2007 Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884-896
14. Turner KJ, Moore JW, Jones A, Taylor CF, Cuthbert-Heavens D, Han C, Leek RD, Gatter KC, Maxwell PH, Ratcliffe PJ, Cranston D, Harris AL 2002 Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62: 2957-2961
15. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS 2008 Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26: 3403-3410
16. Institutes of Health 2008 Evaluation of sunitinib malate in patients with von Hippel-Lindau syndrome (VHL) who have VHL lesions to follow. http://www. clinicaltrials.gov/ct/show/NCT00330564. Accessed July 21, 2008.
17. Zielke A, Middeke M, Hoffmann S, Colombo-Benkmann M, Barth P, Hassan I, Wunderlich A, Hofbauer LC, Duh QY 2002 VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery 132:1056-1063; discussion 1063
18. Salmenkivi K, Heikkila P, Liu J, Haglund C, Arola J 2003 VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. APMIS 111:458-464
19. Favier J, Plouin PF, Corvol P, Gasc JM 2002 Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol 161:1235-1246
20. Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, Bertagna X, Schlumberger M, Jeunemaitre X, Gimenez-Roqueplo AP, Plouin PF 2007 Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 92: 3822-3828
21. Timmers HJ, Pacak K, Huynh TT, Abu-Asab M, Tsokos M, Merino MJ, Baysal BE, Adams KT, Eisenhofer G 7 October 2008 Biochemically silent abdominal paragangliomas in patients with mutations in the Sdhb gene. J Clin Endocrinol Metab 10.1210/jc.2008-1093
22. Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, Pacak K 2006 High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab 91:4505-4509
23. Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, Kung AL, Sanso G, Powers JF, Tischler AS, Hodin R, Heitritter S, Moore F, Dluhy R, Sosa JA, Ocal IT, Benn DE, Marsh DJ, Robinson BG, Schneider K, Garber J, Arum SM, Korbonits M, Grossman A, Pigny P, Toledo SP, Nose V, Li C, Stiles CD 2005 A HIF1α regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 1:72-80
24. Timmers HJ, Pacak K, Bertherat J, Lenders JW, Duet M, Eisenhofer G, Stratakis CA, Niccoli-Sire P, Tran BH, Burnichon N, Gimenez-Roqueplo AP 2008 Mutations associated with succinate dehydrogenase D-related malignant paragangliomas. Clinical Endocrinol (Oxf) 68:561-566
25. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin Jr WG, Schlisio S 2005 Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer cell 8:155-167